✦ LIBER ✦

T790M mutation is associated with better efficacy of treatment beyond progression with EGFR-TKI in advanced NSCLC patients

✍ Scribed by Li, Wei; Ren, Shengxiang; Li, Jiayu; Li, Aiwu; Fan, Lihong; Li, Xuefei; Zhao, Cao; He, Yayi; Gao, Guanghui; Chen, Xiaoxia; Li, Shuai; Shi, Jingyun; Zhou, Caicun; Fei, Ke; Schmid-Bindert, Gerald

Book ID: 121657042
Publisher: Elsevier Science
Year: 2014
Tongue: English
Weight: 946 KB
Volume: 84
Category: Article
ISSN: 0169-5002
DOI: 10.1016/j.lungcan.2014.03.011

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

27 Risk of CNS progression in EGFR mutat

27 Risk of CNS progression in EGFR mutation positive NSCLC patients treated with TKI

✍ Walter, H.S.; Plant, R.; Chauhan, M.; Fennell, D.A.; Ahmed, S.I. 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 45 KB

PCN63 EPIDERMAL GROWTH FACTOR RECEPTOR (

PCN63 EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATION TESTING AND FIRST LINE TREATMENT WITH GEFITINIB IS A DOMINANT STRATEGY IN THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)

✍ G. de Lima Lopes 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 57 KB

9132 POSTER Efficacy Outcomes in First-l

9132 POSTER Efficacy Outcomes in First-line Treatment of Advanced NSCLC With Gefitinib (G) vs Carboplatin/paclitaxel (C/P) by Epidermal Growth Factor Receptor (EGFR) Gene-copy Number Score and by Most Common EGFR Mutation Subtypes – Exploratory Data From IPASS

✍ Yang, J.; Wu, Y.L.; Saijo, N.; Thongprasert, S.; Chu, D.T.; Chen, Y.M.; Duffield 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 46 KB

PD-159 Mutation in the tyrosine kinase d

PD-159 Mutation in the tyrosine kinase domain of epidermal growthfactor receptor (EGFR) is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer (NSCLC)

✍ Tsai, C.; Chiu, C.; Chou, T.; Li, L.; Chang, K.; Chen, Y.; Tsai, S.; Perng, R. 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 139 KB

P-976 EGFR mutation analysis in a random

P-976 EGFR mutation analysis in a randomized phase II study of cetuximab (Erbitux™) in combination with cisplatin (C) and vinorelbine (V) vs CV alone in the first-line treatment of advanced non-small-cell lung cancer (NSCLC) patients (pts)

✍ Szczesna, A.; Taron, M.; Robinet, G.; Ramlau, R.; Pfeifer, W.; Kolb, R.; Consten 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 117 KB